ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 364

Calcium Pyrophosphate Crystal Arthritis During Hospitalizations: A Prospective, Crystal-Proven Case Series

Laura Ranieri1, Francisca Sivera 2 and Mariano Andrés 3, 1Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, 2Hospital General Universitario de Elda, Elda, Spain, 3Hospital General Universitario de Alicante-ISABIAL, Universidad Miguel Hernández, Alicante, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Calcium pyrophosphate dihydrate (CPPD), pseudogout and chondrocalcinosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Metabolic & Crystal Arthropathies Poster I: Clinical

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite more than fifty years after its initial description, key questions for calcium pyrophosphate (CPP) crystal disease, such as clinical spectrum, diagnosis or management schemes, remain unsolved. Acute flares often occurred during hospitalizations, but scant reports have addressed this common setting for CPP crystal disease. Whether these patients behave similarly to ambulatory cases is unknown. Our aim was to describe a prospective, crystal-proven case series of patients developing acute CPP crystal arthritis during hospitalizations for other conditions.

Methods: Observational, cross sectional descriptive study, conducted in two Spanish centers from November 2013 to December 2018. A prospective convenience sampling was used to select patients with crystal-proven CPP acute arthritis occurred during hospital admissions. Demographic, clinical and CPP-related variables were collected. X-rays of pelvis, knees, hands, and affected joint when different – to assess chondrocalcinosis (CC) – and laboratory tests – to rule out associated metabolic conditions – were systematically requested. A descriptive analysis is presented.

Results: We included 90 episodes of acute CPP arthritis in 87 patients, with an average age of 81.8 years (SD 7.7), 50.6% of them men. 26.4% of patients referred prior flares, most of them (68.4%) as outpatients. Three patients were on flare prophylaxis (colchicine in two, low-dose glucocorticoids in one). The reasons for admission were diverse, with a mean of 7.7 days (SD 9.1) from admission to flare. Flares were mostly monoarticular (81.0%) and involving knees (46.0%). In X-rays, 23.8% of patients showed absence of CC [61/80]; in 57.1%, CC was noted in the affected joint [44/77], while in 74.3% in knees [55/74], 51.5% in triangular carpal ligaments [34/66], 25.4% in metacarpophalangeal joints [17/67], 20% in pubic symphysis [14/70], and 17.6% in coxofemoral joints [12/68]. Secondary osteoarthritis was seen in 10 patients (12.5%). Hyperuricemia was noted in 12 patients (13.3%), hypomagnesemia at the time of the flare in five (5.7%), and one case of primary hyperparathyroidism was diagnosed. In all six patients with a polyarticular presentation, rheumatoid factor and ACPA were negative.

Conclusion: From this prospective, crystal-proven series of CPP crystal arthritis during hospitalizations, we can remark: i) the low numbers of prior flares as outpatients may suggest a different clinical entity; ii) CC was absent in around a quarter of patients despite an extensive assessment, so synovial fluid analysis remains essential for accurate diagnosis; and, iii) the rarity of associated metabolic diseases runs against systematic screening for secondary causes of CPP disease in this setting.


Disclosure: L. Ranieri, None; F. Sivera, None; M. Andrés, Astra-Zeneca, 5, Grunenthal, 2, 5, 8, Horizon, 5, Menarini, 8.

To cite this abstract in AMA style:

Ranieri L, Sivera F, Andrés M. Calcium Pyrophosphate Crystal Arthritis During Hospitalizations: A Prospective, Crystal-Proven Case Series [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/calcium-pyrophosphate-crystal-arthritis-during-hospitalizations-a-prospective-crystal-proven-case-series/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/calcium-pyrophosphate-crystal-arthritis-during-hospitalizations-a-prospective-crystal-proven-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology